Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gabapentin as adjunctive therapy for partial seizures.

J Bruni1

  • 1St. Michael's Hospital, Toronto, Ontario, Canada.

Epilepsia
|October 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group.

Seizure·2000
Same author

Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group.

Seizure·2000
Same author

A STAT cardiac marker system for detecting acute heart attacks.

American clinical laboratory·1999
Same author

Women's issues in the treatment of epilepsy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·1998
Same author

Efficacy of topiramate.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·1998
Same author

Outcome evaluation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. Neurontin Evaluation of Outcomes in Neurological Practice.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·1998
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Gabapentin, as add-on therapy for epilepsy, significantly reduced seizure frequency in patients on other medications. Many patients experienced fewer seizures or became seizure-free, with some reporting improved quality of life.

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Epilepsy management often requires adjunctive therapies for patients with refractory seizures.
  • Established antiepileptic drugs like phenytoin and carbamazepine may not fully control complex partial seizures.

Purpose of the Study:

  • To evaluate the safety, tolerability, and efficacy of gabapentin as adjunctive therapy in epileptic patients.
  • To assess the impact of gabapentin on seizure frequency and quality of life.

Main Methods:

  • A multicenter, open-label prospective study involving 141 epileptic patients.
  • Gabapentin dosage was titrated up to 2400 mg/day over a 20-week treatment period.
  • Quality of life was assessed using the QOLIE-10 questionnaire.

Main Results:

Related Experiment Videos

  • 71% of patients achieved a ≥50% reduction in seizure frequency; 46% became seizure-free.
  • The mean maintenance dose of gabapentin was 1600 mg/day.
  • Significant improvements were noted in 5 out of 10 QOLIE-10 questions.

Conclusions:

  • Gabapentin is a safe and tolerable adjunctive therapy for epilepsy.
  • Gabapentin effectively reduces seizure frequency and improves quality of life in patients with complex partial seizures.
  • Further research may explore optimal dosing and long-term outcomes.